A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Key Who May Qualify: - Previously untreated with histological confirmation of AML by World Health Organization 2022 criteria and are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity. - Participant has any level of CD123 expression on blasts. - Participants must be considered ineligible for intensive chemotherapy, defined by the following: - ≥75 years of age; or - ≥18 to 74 years of age with at least 1 of the following: - Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3. - Diffusing capacity of the lung for carbon monoxide of ≤65% or forced expiratory volume in 1 second ≤65%. - Baseline kidney function (creatinine clearance) at least 30 to \<45 milliliters/minute calculated by the Cockcroft Gault formula or measured by 24-hour urine collection. - Hepatic disorder with total bilirubin \>1.5 x upper limit of normal. - Any other condition for which the physician judges the participant to be unsuitable for intensive chemotherapy. - ECOG performance status: - 0 to 2 for participants ≥75 years of age, or - 0 to 3 for participants ≥18 to 74 years of age. Key Who Should NOT Join This Trial: - Participant has received prior therapy for AML. - Participant is willing and able to receive standard induction therapy. - Participant has received treatment for an antecedent hematologic disease with a hypomethylating agent, venetoclax, tagraxofusp, purine analogue, cytarabine, intensive chemotherapy, SCT, chimeric antigen receptor-T therapy, or other experimental therapies. - Participant has AML with central nervous system involvement. Note: Other inclusion/exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.